



(51) International Patent Classification:

C07K 16/28 (2006.01) **A61P 35/00** (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2018/072271

(22) International Filing Date:

16 August 2018 (16.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/546,322 16 August 2017 (16.08.2017) US
62/582,653 07 November 2017 (07.11.2017) US
62/582,666 07 November 2017 (07.11.2017) US
PCT/EP2018/065237
08 June 2018 (08.06.2018) EP

(71) Applicant: **TUSK THERAPEUTICS LTD** [GB/GB];
Stevenage Bioscience Catalyst, Accelerator Building, Gun-
nells Wood Road, Stevenage Hertfordshire SG1 2FX (GB).

(72) Inventors: **GOUBIER, Anne**; c/o Tusk Therapeutics
Limited, Stevenage Bioscience Catalyst, Gunnells Wood
Road, Stevenage Hertfordshire SG1 2FX (GB). **SALIMU,
Josephine**; c/o Tusk Therapeutics Limited, Stevenage Bio-
science Catalyst, Gunnells Wood Road, Stevenage Hert-
fordshire SG1 2FX (GB). **GOYENECHEA, Beatriz**; c/o
Tusk Therapeutics Limited, Stevenage Bioscience Catalyst,
Gunnells Wood Road, Stevenage Hertfordshire SG1 2FX
(GB). **MERCHERS, Pascal**; c/o Tusk Therapeutics Lim-


ited, Stevenage Bioscience Catalyst, Gunnells Wood Road,
Stevenage Hertfordshire SG1 2FX (GB). **MOULDER,
Kevin**; c/o Tusk Therapeutics Limited, Stevenage Bio-
science Catalyst, Gunnells Wood Road, Stevenage Hertford-
shire SG1 2FX (GB). **EISSLER, Nina**; c/o Tusk Therapeu-
tics Limited, Stevenage Bioscience Catalyst, Gunnells Wood
Road, Stevenage Hertfordshire SG1 2FX (GB). **FILOSTO,
Simone**; c/o Tusk Therapeutics Limited, Stevenage Bio-
science Catalyst, Gunnells Wood Road, Stevenage Hertford-
shire SG1 2FX (GB). **BARUAH, Hemanta**; c/o Adimab,
LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766
(US). **PRINZ, Bianca**; c/o Adimab, LLC, 7 Lucent Drive,
Lebanon, New Hampshire 03766 (US).

(74) Agent: **LEONARD, Thomas Charles**; Kilburn & Strode
LLP, Lacon London, 84 Theobalds Road, London London
WC1X 8NL (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: CD38 MODULATING ANTIBODY



(57) Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

[Continued on next page]



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))